(Part two of a four-part series)

Regarding small psilocybin doses, a recently published crowd-sourced research site found that 953 people who microdose showed on average greater improvement in mental health and mood over one month compared to 180 who do not microdose.

As a mycologist and advocate Paul Stamets recently said in an interview with Double Blind magazine, “microdosing, by definition, is sub-sensory. If you take psilocybin mushrooms and you feel an effect, that’s not microdosing.”

The research’s novelty was that it included a non-microdosing control group. It assessed past-month psychedelic practices, mood and mental health and presented tasks testing cognitive and psychomotor processing, completed both at the study outset and on the following 22 to 35 days.

The results showed that the microdosing participants were more likely to be older, white and full-time employees as compared to the non-microdosers. The former experienced greater improvement from baseline after one month, with depression levels shifting from moderate to mild after 30 days of microdosing with anxiety, stress scores, positive mood and larger decreases in negative mood.

These outcomes follow previous …

Full story available on Benzinga.com